 DARTMOUTH, Nova Scotia CAMBRIDGE, Mass.--BUSINESS WIRE--- IMV DeliveryPlatform--IMV Inc. NASDAQ: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recurrent ovarian cancer will be presented at the upcoming Society for Immunotherapy of Cancer SITC Annual Meeting on November 10-14, 2021 in Washington, D 